Literature DB >> 30318826

Extent of portal vein tumour thrombosis in patients with hepatocellular carcinoma: The more, the worse?

Aline Mähringer-Kunz1, Verena Steinle1, Christoph Düber1, Arndt Weinmann2,3, Sandra Koch3, Irene Schmidtmann4, Sebastian Schotten1, Jan B Hinrichs5, Dirk Graafen1, Daniel Pinto Dos Santos6, Peter R Galle2, Roman Kloeckner1.   

Abstract

BACKGROUND & AIMS: Portal vein tumour thrombosis (PVTT) has a significant impact on the prognosis of patients with hepatocellular carcinoma (HCC). The degree of PVTT varies from sub-/segmental invasion to complete occlusion of the main trunk. Aim of this study was to evaluate whether the degree of PVTT correlates with prognosis.
METHODS: A total of 1317 patients with HCC treated at our tertiary referral centre between January 2005 and December 2016 were included. PVTT was diagnosed by contrast-enhanced computed tomography or magnetic resonance imaging. The extent of PVTT was documented according to the Liver Cancer Study Group of Japan classification: Vp0 = no PVTT, Vp1 = segmental portal vein invasion, Vp2 = right anterior/posterior portal vein, Vp3 = right/left portal vein and Vp4 = main trunk. Median overall survival (OS) was calculated for each group.
RESULTS: Portal vein tumour thrombosis was present in 484 (36.8%) patients. Median OS without PVTT was 35.7 months, significantly longer than in patients with PVTT (7.2 months, P < 0.001). The patients with PVTT were subclassified as follows: 103 Vp1, 87 Vp2, 143 Vp3 and 151 Vp4. The corresponding median OS yielded 14.6, 9.4, 5.8 and 4.8 months for Vp1-Vp4, respectively (P < 0.001).
CONCLUSIONS: Portal vein tumour thrombosis in patients with HCC is associated with a dismal prognosis. The results indicate an association between the extent of PVTT and OS. However, the extent of PVTT is not that decisive, as even minor PVTT leads to a very poor prognosis. Therefore, meticulous evaluation of cross-sectional imaging is crucial for the clinical management of patients with HCC.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  hepatocellular carcinoma; portal vein; thrombosis

Mesh:

Year:  2018        PMID: 30318826     DOI: 10.1111/liv.13988

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  17 in total

Review 1.  Tumor in vein (LR-TIV) and liver imaging reporting and data system (LI-RADS) v2018: diagnostic features, pitfalls, prognostic and management implications.

Authors:  Roberta Catania; Kalina Chupetlovska; Amir A Borhani; Ekta Maheshwari; Alessandro Furlan
Journal:  Abdom Radiol (NY)       Date:  2021-09-14

2.  Adaptation of lenvatinib treatment in patients with hepatocellular carcinoma and portal vein tumor thrombosis.

Authors:  Takanori Mukozu; Hidenari Nagai; Daigo Matsui; Kunihide Mohri; Go Watanabe; Naoyuki Yoshimine; Makoto Amanuma; Kojiro Kobayashi; Yu Ogino; Yasushi Matsukiyo; Teppei Matsui; Yasuko Daido; Noritaka Wakui; Mie Shinohara; Koichi Momiyama; Koji Higai; Yoshinori Igarashi
Journal:  Cancer Chemother Pharmacol       Date:  2021-10-10       Impact factor: 3.333

Review 3.  Neoadjuvant radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a systematic review.

Authors:  Zhewen Wei; Jianjun Zhao; Xinyu Bi; Yefan Zhang; Jianguo Zhou; Zhiyu Li; Zhen Huang; Hong Zhao; Jianqiang Cai
Journal:  Hepatobiliary Surg Nutr       Date:  2022-10       Impact factor: 8.265

4.  A Powerful Nomogram Based on the Novel D-Index to Predict Prognosis After Surgical Resection of Hepatocellular Carcinoma.

Authors:  Xia Du; Cheng-Nan Guo; Xiao-Dong Bao
Journal:  Cancer Manag Res       Date:  2021-03-17       Impact factor: 3.989

5.  The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study.

Authors:  Aline Mähringer-Kunz; Verena Steinle; Roman Kloeckner; Sebastian Schotten; Felix Hahn; Irene Schmidtmann; Jan Bernd Hinrichs; Christoph Düber; Peter Robert Galle; Hauke Lang; Arndt Weinmann
Journal:  PLoS One       Date:  2021-05-07       Impact factor: 3.240

6.  Safety and efficacy of endovascular implantation of a portal vein stent combined with iodine-125 seed-strips followed by transcatheter arterial chemoembolization with sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis.

Authors:  Shuangxi Li; Lei Li; Baohua Li; Wenhui Wang
Journal:  Br J Radiol       Date:  2020-06-03       Impact factor: 3.039

Review 7.  Hepatocellular carcinoma: metastatic pathways and extra-hepatic findings.

Authors:  Sandeep Arora; Carla Harmath; Roberta Catania; Ari Mandler; Kathryn J Fowler; Amir A Borhani
Journal:  Abdom Radiol (NY)       Date:  2021-06-05

8.  Hepatic vein tumor thrombosis in patients with hepatocellular carcinoma: Prevalence and clinical significance.

Authors:  Aline Mähringer-Kunz; Franziska I Meyer; Felix Hahn; Lukas Müller; Christoph Düber; Daniel Pinto Dos Santos; Peter R Galle; Arndt Weinmann; Roman Kloeckner; Sebastian Schotten
Journal:  United European Gastroenterol J       Date:  2021-06-02       Impact factor: 4.623

9.  Safety and efficacy of drug-eluting bead transarterial chemoembolization with CalliSpheres® microsphere for hepatocellular carcinoma with portal vein tumor thrombus: a preliminary study.

Authors:  Tan-Yang Zhou; Sheng-Qun Chen; Hong-Liang Wang; Sheng-Ming Weng; Guan-Hui Zhou; Yue-Lin Zhang; Chun-Hui Nie; Tong-Yin Zhu; Bao-Quan Wang; Zi-Niu Yu; Li Jing; Feng Chen; Jun-Hui Sun
Journal:  J Cancer       Date:  2021-06-01       Impact factor: 4.207

10.  Efficacy and Safety of Transarterial Chemoembolization in Elderly Patients of Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Retrospective Study.

Authors:  Qinghe Tang; Wei Huang; Jun Liang; Junli Xue
Journal:  Front Oncol       Date:  2021-07-07       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.